1. Home
  2. PRVA vs TNGX Comparison

PRVA vs TNGX Comparison

Compare PRVA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Privia Health Group Inc.

PRVA

Privia Health Group Inc.

HOLD

Current Price

$24.81

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$21.53

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRVA
TNGX
Founded
2007
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PRVA
TNGX
Price
$24.81
$21.53
Analyst Decision
Buy
Strong Buy
Analyst Count
12
10
Target Price
$31.17
$21.78
AVG Volume (30 Days)
690.6K
2.8M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
26.89
EPS
0.18
N/A
Revenue
$2,122,842,000.00
$62,384,000.00
Revenue This Year
$18.19
N/A
Revenue Next Year
$10.72
N/A
P/E Ratio
$137.50
N/A
Revenue Growth
22.26
48.29
52 Week Low
$18.78
$1.04
52 Week High
$26.51
$28.41

Technical Indicators

Market Signals
Indicator
PRVA
TNGX
Relative Strength Index (RSI) 68.00 45.80
Support Level $22.63 $6.83
Resistance Level $25.23 $22.01
Average True Range (ATR) 0.74 1.87
MACD 0.16 -0.60
Stochastic Oscillator 98.18 17.19

Price Performance

Historical Comparison
PRVA
TNGX

About PRVA Privia Health Group Inc.

Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: